Guidelines & instruction to submit the Abstract:

1. The abstract must be written in English Only.
2. The body of abstract should not exceed 300 words.
3. Give a title to the abstract. The title should be in CAPITAL LETTERS.
4. Only Presenting Author may submit the abstract.
5. The abstract should only be submitted online.
6. The last date for submission of abstract is 15th October

Online Abstract Submission Form

First time users
 If you are submitting an abstract for the Microbicides 2008, kindly click here to access the abstract form

Confirmation letter:
After the successful submission of an abstract, you will receive an automatic acknowledgement e-letter. You will have an access to your abstract submitted through the username and password already received by you for editing, printing, downloading and withdrawal of the abstract.

• In case you want to edit the abstract submitted initially, kindly click Edit
• In case you want to submit second or more abstract, kindly click more Abstract

• As you click the above link will access the login page to put in your username and password.
• Changes in the abstract can only be made prior to October 15th 2007.

• The abstract review committee and the scientific committee reserve the right to accept or reject the abstract.
• In case of any problems faced during the submission of the abstract, please contact us on m2008@microbicides2008.com

TRACK A Basic Sciences
	A.1	Sexual transmission of HIV: New findings
	A.2	Innate and adaptive immunity: Role in HIV mucosal acquisition and control
	A.3	Latest developments in biomarkers and in vitro models of efficacy and safety
	A.4	Animal models: Current status and latest data
	A.5	Emerging microbicide candidates
	A.6	Biological role of STIs in HIV transmission
	A.7	Formulation and delivery strategies
TRACK B Clinical
	B.1	Empirical findings of Phase I and II clinical trials of new microbicide products including rectal microbicides
	B.2	Adherence and compliance to trial procedures and product use: measurement, strategies, impact on retention and recruitment
	B.3	Effectiveness trial status and presentation of baseline participant data
	B.4	Alternative microbicide strategies and the role of STIs in HIV prevention
	B.5	Barrier method strategies
	B.6	Testing methods/ algorithsm for measuring HIV end-points including HIV incidence
	B.7	Alternative microbicide efficacy trials designs
TRACK C Socio-behavioural
	C.1	Acceptability: initiation and use of various microbicide formulations and delivery mechanisms in different geographic settings and populations. Discussion of theoretical frameworks to examine acceptability encouraged
	C.2	Adherence: including development of adherence-related measures, triangulation of data collection methods and/or analysis procedures, use of social science theory and/or research methods to boost adherence within trials - or in future service delivery settings
	C.3	Rectal Microbicides: prevalence of anal sex in men and women; acceptability of microbicide gel for rectal use
	C.4	Male Involvement in Microbicide Research: partner consent for trial participation; male acceptability of microbicides; influence of trial participation and microbicide use on sexual partnerships
	C.5	Social Science research on Standards of Care: participant and/or community research on attitudes towards SOC levels, research on ethics and informed consent issues
	C.6	Supporting Clinical trials: social science research on recruitment, informed consent, retention, assessing adherence, closing out trials
	C.7	Access to Microbicides beyond Clinical Trials: focus on how providers, product costs and service delivery mechanisms may influence microbicide accessibility, acceptability and use in a post-marketing situation. Drawing lessons from other HIV prevention research studies
Track D Policy, Advocacy and Community
	D.1	Policy
	Policies that support microbicide development and research, and access. Involvement of positive people and their role in developing and implementing policy (and research) Standards of prevention, treatment and care for trial participants – policy issues
	D.2	Advocacy:
	Microbicides advocacy aimed at a variety of stakeholders—women, policy makers, trial communities, donors, people with HIV, etc. Preparing stakeholders for research results Ensuring rapid access to proven microbicide products Standards of prevention, treatment and care for trial participants – advocacy issues Mobilising relevant partners (policy makers, donors, agencies, media etc) to support
	D.3	Community:
	Community mobilisation, preparedness and involvement – creating effective partnerships Community Advisory Boards Defining, understanding and involving the community Mobilising communities for microbicides Working with the media